Dyslididemia is a major cause of
increased atherogenic risk and atherosclerosis-associated conditions (IHD, CVD, PVD)
lipid lowering is very beneficial for the treatment of
CVD
1% reduction in total cholesterol->
2% reduction in CHD events
many clinical trials have should that avg dyslipidemic therapy results in
30-40% reduction of fatal/non-fatal CHD events & stroke
primary goal of dyslipidemia therapy
reduction of LDL levels
comparably important dyslipidemia therapy goals
severe hypertriglyceridemia->
(>1000mg/dL)-> pancreatitis
moderate elevation of triglycerides ->
(150-400mg/dL)-> part of metabolic syndrome
1% reduction in LDL->
1% reduction in CHD events
1% increase in HDL->
3% reduction in CHD events
how much cholesterol is biosynthesized in the body daily?
~1000mg
cholesterol is important
statins are
competitive inhibitors of HMG-CoA reductase-> blocks synthesis of cholesterol
HMG-CoA
3-hydroxy-3- methylglutaryl coenzyme A
statins block the conversion of HMG-CoA to
mevalonate
blocked synthesis of cholesterol in the liver leads to
reduction of LDL levels is
dose dependent
TG levels >250mg/dL
-> 35-45% reduction (with max doses)
TG levels <250mg/dL
-> up to 25% reduction
statins also increase HDL levels by
~7.5%
how do statins reduce TG levels
main effect of statins
reduction of LDL & improvement of the lipid profile
pleiotropic effects of statins
pleiotropic effects of statins are independent of
lipid-lowering effects